David Collins, PA
Medical · Boardman, ORNPI 1548320302
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $346 and has fallen 50.1% since, to $173 in 2025.
Across 34 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$147
- AbbVie$147
- Regeneron Healthcare Solutions, Inc.$135
- Johnson & Johnson$124
- Lilly USA, LLC$121
- Sanofi$96
- plus $121 from 4 others
What the payments were for
- Food & beverage$80790%
- Education$8510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 4 | $147 |
| AbbVie | 6 | $147 |
| Regeneron Healthcare Solutions, Inc. | 5 | $135 |
| Johnson & Johnson | 3 | $124 |
| Lilly USA, LLC | 7 | $121 |
| Sanofi | 4 | $96 |
| Novartis | 2 | $50 |
| UCB, Inc. | 1 | $33 |
| LEO Pharma Inc. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $16 |
How this compares
$892 in reported general payments places this provider in the 70th percentile of 364 medical providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 13 | $267,410 |
| Dupixent PenDupilumab | 13 | $47,852 |
| Ketoconazole | 157 | $3,505 |
| Fluorouracil | 52 | $2,706 |
| Fluocinonide | 61 | $2,043 |
| Betamethasone Dipropionate | 26 | $1,751 |
| Triamcinolone Acetonide | 171 | $1,298 |
| Tacrolimus | 14 | $908 |
| Doxycycline Monohydrate | 50 | $863 |
| Clindamycin Phosphate | 14 | $653 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 56 | $647 |
| Metronidazole | 13 | $467 |
| Mupirocin | 39 | $386 |
| ErythromycinErythromycin Base In Ethanol | 11 | $361 |
| Clobetasol Propionate | 13 | $254 |
Paid to pharmacies, not to this prescriber.
Other medical in Boardman
- Mark DavisLake Oswego$12K
- Britt BennPortland$11K
- Benjamin WillettSalem$11K
- Jeffrey RennaSalem$9K
- Christy SnoSpringfield$8K
- Erica BallardPortland$8K
- Nicole WydraCorvallis$8K
- Caitlyn EricksonHillsboro$6K
- Brolin JohnsonSalem$6K
- Maci PfaffenbergerGresham$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.